Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 15

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Molecular and clinical features of the TP53 signature gene expression profile in early-stage breast cancer

Yamaguchi, Shigeo, Takahashi, Shin, Mogushi, Kaoru, Izumi, Yuki, Nozaki, Yumi, Nomizu, Tadashi, Kakugawa, Yoichiro, Ishida, Takanori, Ohuchi, Noriaki, Ishioka, Chikashi, Kato, Shunsuke·2018·Oncotarget
DOI 10.18632/oncotarget.24447
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.24447

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 42

  1. Fischer, 2017, Census and evaluation of p53 target genes, Oncogene, 36, 3943, 10.1038/onc.2016.502 · DOI · Paper page
  2. Vousden, 2013, p53 mutations in cancer, Nat Cell Biol, 15, 2, 10.1038/ncb2641 · DOI · Paper page
  3. Cancer Genome Atlas Network, 2012, Comprehensive molecular portraits of human breast tumours, Nature, 490, 61, 10.1038/nature11412 · DOI · Paper page
  4. Khattra, 2012, The clonal and mutational evolution spectrum of primary triple-negative breast cancers, Nature, 486, 395, 10.1038/nature10933 · DOI · Paper page
  5. Borresen-Dale, 2003, TP53 and breast cancer, Hum Mutat, 21, 292, 10.1002/humu.10174 · DOI · Paper page
  6. Papaspyrou, 2006, Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy, Ann Oncol, 17, 1504, 10.1093/annonc/mdl147 · doi:10.1093/annonc/mdl147
  7. Uhrhammer, 2006, The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer, Clin Cancer Res, 12, 1157, 10.1158/1078-0432.ccr-05-1029 · DOI · Paper page
  8. Ishioka, 2003, Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis, Proc Natl Acad Sci U S A, 100, 8424, 10.1073/pnas.1431692100 · DOI · Paper page
  9. Iggo, 2017, Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice, Cancer Res, 77, 1250, 10.1158/0008-5472.can-16-2179 · DOI
  10. Ishioka, 2008, Prediction of breast cancer prognosis by gene expression profile of TP53 status, Cancer Sci, 99, 324, 10.1111/j.1349-7006.2007.00691.x · doi:10.1111/j.1349-7006.2007.00691.x
  11. Noguchi, 2014, Significance of TP53 mutations determined by next-generation “deep” sequencing in prognosis of estrogen receptor-positive breast cancer, Cancer Lett, 342, 19, 10.1016/j.canlet.2013.08.028 · DOI
  12. Yi, 2015, Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value, BMC Cancer, 15, 179, 10.1186/s12885-015-1102-7 · DOI
  13. Goulioti, 2016, 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer, N Engl J Med, 375, 717, 10.1056/NEJMoa1602253 · DOI · Paper page
  14. Roberts, 2002, Gene expression profiling predicts clinical outcome of breast cancer, Nature, 415, 530, 10.1038/415530a · DOI · Paper page
  15. Therasse, 2006, Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer, J Natl Cancer Inst, 98, 1183, 10.1093/jnci/djj329 · DOI · Paper page
  16. Roth, 2013, The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis, Breast Cancer Res Treat, 141, 13, 10.1007/s10549-013-2666-z · DOI · Paper page
  17. Paik, 2008, Development of the 21-gene assay and its application in clinical practice and clinical trials, J Clin Oncol, 26, 721, 10.1200/jco.2007.15.1068 · DOI · Paper page
  18. Mitton, 2008, Direct multiplexed measurement of gene expression with color-coded probe pairs, Nat Biotechnol, 26, 317, 10.1038/nbt1385 · DOI · Paper page
  19. Kamel-Reid, 2011, mRNA transcript quantification in archival samples using multiplexed, color-coded probes, BMC Biotechnol, 11, 46, 10.1186/1472-6750-11-46 · DOI · Paper page
  20. Lonning, 2012, Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer, Breast Cancer Res, 14, R47, 10.1186/bcr3147 · DOI
  21. Knappskog, 2013, Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers, Oncogene, 32, 5315, 10.1038/onc.2013.48 · DOI
  22. Lonning, 2012, P53 and its molecular basis to chemoresistance in breast cancer, Expert Opin Ther Targets, 16, S23, 10.1517/14728222.2011.640322 · DOI
  23. Hotta, 2016, Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer, N Engl J Med, 375, 1823, 10.1056/NEJMoa1606774 · DOI · Paper page
  24. de Castro, 2016, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet, 387, 1540, 10.1016/s0140-6736(15)01281-7 · DOI · Paper page
  25. O’Day, 2015, Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial, Lancet Oncol, 16, 908, 10.1016/s1470-2045(15)00083-2 · DOI · Paper page
  26. Neyns, 2015, Pembrolizumab versus Ipilimumab in Advanced Melanoma, N Engl J Med, 372, 2521, 10.1056/NEJMoa1503093 · DOI · Paper page
  27. Moreira, 2015, Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, 348, 124, 10.1126/science.aaa1348 · DOI · Paper page
  28. Snyder, 2015, Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma, N Engl J Med, 373, 1984, 10.1056/NEJMc1508163 · DOI · Paper page
  29. Elledge, 2017, Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy, Science, 355, 10.1126/science.aaf8399 · DOI · Paper page
  30. Fu, 2016, Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade, Cancer Cell, 29, 285, 10.1016/j.ccell.2016.02.004 · DOI · Paper page
  31. Wu, 2016, Potential biomarker for checkpoint blockade immunotherapy and treatment strategy, Tumour Biol, 37, 4251, 10.1007/s13277-016-4812-9 · DOI
  32. Lawrence, 2014, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, 515, 563, 10.1038/nature14011 · DOI · Paper page
  33. Carbone, 2016, Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer, J Thorac Oncol, 11, 976, 10.1016/j.jtho.2016.02.015 · DOI · Paper page
  34. Diab, Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer, European Journal of Cancer, 72, S16, 10.1016/S0959-8049(17)30131-4 · doi:10.1016/s0959-8049(17)30131-4
  35. Gingeras, 2013, STAR: ultrafast universal RNA-seq aligner, Bioinformatics, 29, 15, 10.1093/bioinformatics/bts635 · DOI · Paper page
  36. Shi, 2014, featureCounts: an efficient general purpose program for assigning sequence reads to genomic features, Bioinformatics, 30, 923, 10.1093/bioinformatics/btt656 · DOI · Paper page
  37. Lengauer, 2005, ROCR: visualizing classifier performance in, R. Bioinformatics, 21, 3940, 10.1093/bioinformatics/bti623 · DOI · Paper page
  38. Haibe-Kains, 2016, Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer, Bioinformatics, 32, 1097, 10.1093/bioinformatics/btv693 · DOI · Paper page
  39. Haibe-Kains, 2011, survcomp: an R/Bioconductor package for performance assessment and comparison of survival models, Bioinformatics, 27, 3206, 10.1093/bioinformatics/btr511 · DOI · Paper page
  40. Leisch, 2010, Mixtures of regression models for time course gene expression data: evaluation of initialization and random effects, Bioinformatics, 26, 370, 10.1093/bioinformatics/btp686 · DOI
  41. Lempicki, 2009, Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources, Nat Protoc, 4, 44, 10.1038/nprot.2008.211 · DOI · Paper page
  42. Lempicki, 2009, Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists, Nucleic Acids Res, 37, 1, 10.1093/nar/gkn923 · DOI · Paper page

Cited by

See all 15

Metadata

Authors
Yamaguchi, S., Takahashi, S., Mogushi, K., Izumi, Y., Nozaki, Y., Nomizu, T., Kakugawa, Y., Ishida, T., Ohuchi, N., Ishioka, C., & Kato, S.
Affiliations
  • Department of Clinical Oncology, Juntendo University Graduated School, Tokyo 113-8421, Japan
  • Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Sendai 980-8575, Japan
  • Diagnostics and Therapeutics of Intractable Diseases, Intractable Disease Research Center, Juntendo University Graduated School, Tokyo 113-8421, Japan
  • Department of Surgery, Hoshi General Hospital, Fukushima 963-8501, Japan
  • Department of Breast Oncology, Miyagi Cancer Center Hospital, Natori 981-1293, Japan
  • Department of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan
Venue
Oncotarget
Publisher
Impact Journals, LLC
Published
2018-02-08
Volume
9
Issue
18
Pages
14193-14206
ISSN
1949-2553
DOI
10.18632/oncotarget.24447
Cited by
15
References
2
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular and clinical features of the TP53 signature gene expression profile in early-stage breast cancer. https://app.cochat.ai/papers/10.18632/oncotarget.24447
The paper
Yamaguchi, S., Takahashi, S., Mogushi, K., Izumi, Y., Nozaki, Y., Nomizu, T., Kakugawa, Y., Ishida, T., Ohuchi, N., Ishioka, C., & Kato, S. (2018). Molecular and clinical features of the TP53 signature gene expression profile in early-stage breast cancer. Oncotarget. https://doi.org/10.18632/oncotarget.24447

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.